Fig. 3: Analogs of GC376 developed as SARS-CoV-2 3CL protease inhibitors.
Structures of GC376 and its analogs were shown, with modifications highlighted in red.
Fig. 3: Analogs of GC376 developed as SARS-CoV-2 3CL protease inhibitors. | Nature Communications
